Actively Recruiting
NANOFER-THE-0504 Evaluating Safety and Dose of THE-0504 Administered Intravenously in Adults With Solid Tumors
Led by Thena Biotech S.r.l. · Updated on 2026-06-12
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase I clinical trial to evaluate the safety and tolerability of a new antitumor drug called THE-0504 in adults with various solid tumors. The study aims to determine the maximum tolerated dose and recommended phase 2 dose while also gathering early data on the drugs safety, antitumor activity, pharmacokinetics, pharmacodynamics, and immune response in humans. Participants will receive THE-0504 administered intravenously on day 1 and day 8 of a 21-day cycle following a dose escalation schedule based on a modified Fibonacci sequence. Dose escalation follows a classic 33 design, allowing for intra-patient dose increases to reduce the risk of underdosing. The study starts treatment for each new patient 21 days after the first patients initial dose in each cohort, and the results will inform further clinical development. During the study, participants will undergo safety assessments, laboratory tests, and monitoring of side effects, immune response, and antitumor effects using established criteria. Pharmacokinetic sampling will occur pre-dose and at multiple time points after dosing in the first three cycles. Patients will be followed for up to 36 months to assess response rates, progression-free survival, and overall survival. Safety monitoring will continue for 90 days after the last dose, and performance status will be tracked throughout.
CONDITIONS
Brief Title
THE-0504 in Patients With Solid Tumors
Research Team
P
Pierpaolo Ceci, PhD
G
Gennaro Daniele, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here